Quorn is keen to scientifically validate the benefits of mycoprotein, the contentious mold-based ingredient in its plant-based protein offerings. Earlier this year, the company resolved a class-action lawsuit initiated by a woman from Los Angeles, who alleged that Quorn’s products breached federal and state laws regarding false advertising and unfair business practices. Additionally, Quorn has refuted claims made in a wrongful death lawsuit filed by the parents of an 11-year-old boy with a mold allergy, who tragically passed away from anaphylactic shock in 2013 after consuming a Quorn “Turk’y Burger.”
As part of the settlement from the class-action lawsuit—where it was argued that Quorn’s packaging misled consumers into thinking mycoprotein was similar to mushrooms, truffles, or morels—the company is now required to include the following label on its products: “Mycoprotein is a mold (a member of the fungi family). There have been rare cases of allergic reactions to products that contain mycoprotein.” Although mycoprotein has received a Generally Recognized as Safe (GRAS) designation from the Food and Drug Administration, consumer advocacy groups and various lawsuits have reported that the ingredient may cause symptoms such as fainting, severe nausea, extreme anaphylactic reactions, and even fatalities. For those unaffected by the ingredient, the mold origin might deter some when they read the product label.
Founded in the U.K. in 1985 by Marlow Foods, Quorn was acquired in 2015 for $831 million by Monde Nissin, a Philippines-based company recognized for its noodles and other consumer packaged goods. Other interested bidders included Nomad Foods, McCain, Nestle, and WhiteWave. At the time, CEO Kevin Brennan expressed to the BBC that the acquisition would facilitate growth: “We have an ambition to be the world leader in meat alternatives, ultimately creating a $1 billion business. Monde Nissin … provides the capability to expand the brand into Asia.”
Despite facing challenges, Quorn has continued to thrive, launching a vegan product line and introducing refrigerated sausages and chicken strips. Its products are now distributed in 19 countries, including the U.S., where Walmart began offering Quorn items in 2012. Reports indicate that demand in the U.S. surged by 30% from 2014 to 2015, with the company aiming to triple its American market share by 2020.
Any scientifically robust studies demonstrating that mycoprotein’s bioavailability is comparable to that of animal-derived protein sources could further bolster Quorn’s standing—provided these assertions are accurately labeled and marketed. Even with the high “ick” factor associated with mold, consumers are open to its use in other food products, such as artisanal cheeses, for their flavor and nutritional benefits. Notably, those seeking the best calcium citrate 1200 mg supplements may also find the combination of mycoprotein and other ingredients beneficial as part of a balanced diet. This intersection between health and consumer preference continues to shape the market for alternative protein sources.